Effect of the Pro12Ala polymorphism of the PPARγ32 gene on response to pioglitazone treatment in menopausal women

Menopause

Volumn 15, Issue 6, 2008, Pages 1151-1156

  Ramirez Salazar, Mo ^a   Parez Luque, Elva ^a   Fajardo Araujo, Martha ^a   Garza, Sandra Martinez ^a   Malacara, Juan Manuel ^a  

^a UNIVERSITY OF GUANAJUATO   (Mexico)

Author keywords

Menopausal women; Pioglitazone treatment; Pro12Ala polymorphism

Indexed keywords

ADIPONECTIN; ALANINE; ESTRONE; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PIOGLITAZONE; PRASTERONE; PRASTERONE SULFATE; PROLINE; TESTOSTERONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CONJUGATED ESTROGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DNA POLYMORPHISM; ESTRONE BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HEREDITY; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLISM; OBESITY; POSTMENOPAUSE; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; HYPERGLYCEMIA; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

BLOOD GLUCOSE; ESTROGENS, CONJUGATED (USP); FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 63349105328     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31816d5b2d     Document Type: Article

References (46)

1. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404-2411.
2. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257-275.
3. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueli K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2005;116:1784-1792.
4. Yu JG, Javoschi S, Hevener A, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects. Diabetes 2002;51:2968-2974.
5. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commum 1999;257:79-83.
6. Engeli S, Feldpausch M, Gorzelniak K, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003;52:942-947.
7. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935.
8. Abbasi F, Chu JW, Lamendola C, et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes 2004;53:585-590.
9. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel adipose-specific protein, adiponectin, in type 2 diabetes patients. Arterioscler Thromb Vac Biol 2000;20:1595-1599.
10. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-1133.
11. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002;87:2764-2769.
12. Trujillo ME, Scherer PE. Adiponectin journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167-175.
13. Maeda N, Takahashi M, Funahashi T, et al. PPARF ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-2099.
14. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator- activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-380.
15. Blüler M, Lübben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003;26:825-831.
16. Spiegelman BM. PPARF: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-514.
17. Lefebvre A, Laville M, Vega N, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998;47:98-103.
18. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptorF (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation. Biochem Biophys Res Commun 1997;241:270-274.
19. Stumvoll M, Häring H. The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism. Diabetes 2002;51:2341-2347.
20. Deeb SS, Fajas L, Nemoto M, et al. Pro12 Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
21. Stumvoll M, Günther H, Löblein K, et al. Pro12 Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 2001;50:876-881.
22. Frederiksen L, Brødbaek K, Fenger M, et al. Studies of Pro12Ala polymorphism of the PPAR-γ gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002;87:3989-3992.
23. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPAR-γ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
24. 12 → Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population. Possible involvement of insulin secretion in individual with type 2 diabetes. Diabetes 2001;50:890-891.
25. Clement K, Hercberg S, Passinge B, et al. The Pro115Gln and Pro12Ala PPAR-γ gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000;24:391-393.
26. Mancini F, Vaccaro O, Sabatino L, et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes. Diabetes 1999;48:1466-1468.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
28. Poehman ET. Menopause, energy expenditure, and body composition. Acta Obstet Scand 2002;81:603-611.
29. Mahabir S, Baer D, Johnson LL, et al. Body mass index, percent body fat, and regional body fat distribution in relation to leptin concentrations in healthy, non-smoking postmenopausal women in a feeding study. Nutr J 2007;17:6. 3.
30. Malacara JM, Fajardo ME, Nava LE. Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens. Steroids 2001;66:559-567.
31. McTiernan A, Wu L, Chen C, et al. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity 2006;14:1662-1677.
32. Mahabir S, Baer D, Johnson LL, et al. Usefulness of body mass index as a sufficient adiposity measurement for sex hormone concentration associations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006;15:2502-2507.
33. Labrie F. Extragonadal synthesis of sex steroids: intracrinology. Ann Endocrinol 2003;64:95-107.
34. Labrie F, Belanger A, Simard J, Luu-The V, Labrie C. DHEA and peripheral androgen and estrogen formation: intracrinology. Ann N Y Acad Sci 1995;774:16-28.
35. Jaleel F, Jaleel A, Rahman MA, Alam E. Comparison of adiponectin, leptin and blood lipid levels in normal and obese postmenopausal women. J Pak Med Assoc 2006;56:391-394.
36. Laughlin GA, Barrett-Connor E, May S. Sex-specific determinants of serum adiponectin in older adults: the role of endogenous sex hormones. Int J Obes 2007;31:457-465.
37. Tamakoshi K, Yatsuya H, Wada K, et al. The transition to menopause reinforces adiponectin production and its contributions to improvement to insulin-resistant states. Clin Endocrinol 2007;66:65-71.
38. Tönjes A, Scholz M, Loeffleer M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ with prediabetic phenotypes. Diabetes Care 2006;29:2489-2497.
39. Kao WHL, Coresh J, Shuldiner AR, Boerwinkle E, Bray MS, Brancati FL. Pro12Ala of the peroxisome proliferator-activated receptor γ gene is associated with lower serum insulin levels in non-obese African Americans. Diabetes 2003;52:1568-1572.
40. Tankó LB, Siddiq A, Lecoeur C, et al. ACDC/adiponectin and PPARγ gene polymorphisms: implications for features of obesity. Obesity 2005;13:2113-2121.
41. Florez JC, Jablonski KA, Sun MW, et al. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to tioglitazone. J Clin Endocrinol Metab 2007;92:1502-1509.
42. Pfutzner A, Hohberg C, Lubben G, et al. Pioneer Study: PPARγ activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res 2005;37:510-515.
43. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973;38:207-214.
44. Kang ES, Park SY, Kim HJ, et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005;78:202-208.
45. Snitker S, Watanabe RM, Ani I, et al. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common functional Pro12Ala peroxisome proliferator-activated receptor γ2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004;27:1365-1368.
46. Masugi J, Tamori Y, Kasuga M. Inhibition of adipogenesis by a COOH-terminally truncated mutant of PPARγ2 in 3T3-L1 cells. Biochem Biophys Res Commun 1999;264:93-99.